b'Unleashing tools to acceleratebreakthroughs in human healthReferences8.Ferrer-Font, L. et al. Panel optimization for high-dimensional 1.Rochigneux, P. et al. Mass cytometry reveals classical monocytes, immunophenotyping assays using full-spectrum flow cytometry. NK cells, and ICOS+ CD4+ T cells associated with pembrolizumabCurrent Protocols 1 (2021): e222.efficacy in patients with lung cancer. Clinical Cancer Research 28 (2022): 5,1365,148. 9.Niewold, P. Letter to the editor: High-dimensional flow cytometry2.data: goldmine or fools gold? Cytometry Part A 105 (2024): Boston University poster: Smith, E.L. et al. CYTO poster (2023). Boston425427.University seminar: Snyder-Cappione, J. Exceptional Resolution of Anti-Inflammatory Cytokines Using CyTOF. CYTO (2024). 10. Richard et al., Clinical response and pathway-specific correlates3.A 20-Marker Core Immune Flow Cytometry Panel Optimized forfollowing TIGIT-LAG3 blockade in myeloma: the MyCheckpoint randomized clinical trial. Nature Cancer, 2024.Flexible Whole Blood Preservation Workflows Application Note (FLDM-01322). 11.Owen et al., A Phase II Clinical Trial of Nivolumab and Temozolomide4.Impact of Cryopreservation on Performance of the Maxpar Directfor Neuroendocrine Neoplasms. Clinical Cancer Research, 2023. Immune Profiling System Application Note (FLDM-00089). 12. Smith, N.J. et al. AACR Poster (2024): Comprehensive5.Lanuti, P. et al. A standardized flow cytometry network study forimmunophenotypic strategies to enable equity in remote settings for improved cancer prognosis. AACR (2024).the assessment of circulating endothelial cell physiological ranges. Scientific Reports 8 (2018): 5823. 13. Wang, X.Q. et al. Spatial predictors of immunotherapy response in6.Deep Immune Profiling With the Maxpar Direct Immune Profilingtriple-negative breast cancer. Nature 621 (2023): 868876. System White Paper (FLDM-400247).7.Supplementary data from Park, L.M. et al. OMIP-069: forty-colorfull spectrum flow cytometry panel for deep immunophenotyping of major cell subsets in human peripheral blood. Cytometry Part A 97 (2020): 1,0441,051.Learn more atstandardbio.com/cytof.xtproCORPORATE HEADQUARTERS SALES2 Tower Place, Suite 2000 North America | +1 650 266 6170 | info-us@standardbio.comSouth San Francisco, CA 94080 USA Europe/Middle East/Africa/Russia | +33 1 60 92 42 40 | info-europe@standardbio.comToll-free: 866 359 4354 in the US and Canada Latin America | +1 650 266 6170 | info-latinamerica@standardbio.comFax: 650 871 7152 Japan | +81 3 3662 2150 | info-japan@standardbio.comstandardbio.com China (excluding Hong Kong/Macau) | +86 21 3255 8368 | info-china@standardbio.comAll other Asia-Pacific countries/India/Australia | +1 650 266 6170 | info-asia@standardbio.comLAB-00002 Rev 2 032025Capture the immune markers that matter brochureFor Research Use Only. Not for use in diagnostic procedures.Patent and License Information: www.standardbio.com/legal/notices. Trademarks: www.standardbio.com/legal/trademarks. Any other trademarks are the sole property of their respective owners. 2025 Standard BioTools Inc. All rights reserved.'